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Avoiding Tacrolimus Underexposure and 
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Renal Transplant Recipients: A Single Arm 
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Bodyweight- based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal 
transplantation. However, after transplantation, a meager 38% of patients are on target at first steady- state and it 
can take up to 3 weeks to reach the target tacrolimus predose concentration (C0). Tacrolimus underexposure and 
overexposure is associated with an increased risk of rejection and drug- related toxicity, respectively. To minimize 
subtherapeutic and supratherapeutic tacrolimus exposure in the immediate post- transplant phase, a previously 
developed dosing algorithm to predict an individual’s tacrolimus starting dose was tested prospectively. In this single- 
arm, prospective, therapeutic intervention trial, 60 de novo kidney transplant recipients received a tacrolimus starting 
dose based on a dosing algorithm instead of a standard, bodyweight- based dose. The algorithm included cytochrome 
P450 (CYP)3A4 and CYP3A5 genotype, body surface area, and age as covariates. The target tacrolimus C0, measured 
for the first time at day 3, was 7.5– 12.5 ng/mL. Between February 23, 2019, and July 7, 2020, 60 patients were 
included. One patient was excluded because of a protocol violation. On day 3 post- transplantation, 34 of 59 patients 
(58%, 90% CI 47– 68%) had a tacrolimus C0 within the therapeutic range. Markedly subtherapeutic (< 5.0 ng/mL) and 
supratherapeutic (> 20 ng/mL) tacrolimus concentrations were observed in 7% and 3% of the patients, respectively. 
Biopsy- proven acute rejection occurred in three patients (5%). In conclusion, algorithm- based tacrolimus dosing leads to 
the achievement of the tacrolimus target C0 in as many as 58% of the patients on day 3 after kidney transplantation.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Renal transplant recipients are at risk for underexposure and 
overexposure to tacrolimus, due to its narrow therapeutic range 
and a large interpatient variability in its pharmacokinetics.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Does the use of a starting dose algorithm for tacrolimus after 
renal transplantation minimize underexposure and overexpo-
sure to tacrolimus in the early post- transplant phase?
WHAT DOES THIS STUDY ADD TO OUR 
KNOW-LEDGE?
 A dosing algorithm that includes age, body surface area, and 
CYP3A4 and CYP3A5 genotype, predicts an individual kidney 
transplant recipient’s tacrolimus starting dose successfully in as 
many as 58% of patients.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 The use of this tacrolimus dosing algorithm appears to out-
perform standard, bodyweight- based tacrolimus (start) dosing 
and has the potential to reduce tacrolimus exposure outside the 
target concentration range.
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Bodyweight- based tacrolimus dosing followed by dose titration 
based on whole- blood concentrations, a practice known as ther-
apeutic drug monitoring (TDM), is standard clinical care after 
solid organ transplantation.1 According to the manufacturer’s in-
structions, the tacrolimus starting dose should be 0.1– 0.2 mg/kg 
bodyweight per day.2 However, the available evidence to support 
this strategy is thin.3 Bodyweight is a poor predictor of tacroli-
mus clearance and, as a result, many patients are overdosed or un-
derdosed in the critical early post- transplant phase.4– 6 Previous 
studies demonstrated that only 18.5– 37.4% of renal transplant 
recipients were within the target tacrolimus predose concentra-
tion (C0) range at first steady- state following initial bodyweight- 
based tacrolimus dosing.7– 9 In addition, and despite the use of 
TDM, it can take up to 3 weeks before a transplant recipient is 
on target.7,9
Age, albumin, body surface area (BSA), comedication, cyto-
chrome P450 (CYP) 3A genotype, ethnicity, and hematocrit 
influence tacrolimus pharmacokinetics.10– 13 Population pharma-
cokinetic (popPK) models and dosing equations incorporating 
these variables have been developed to predict an individual trans-
plant recipient’s tacrolimus dose requirement.1,6,11,13– 27 Clinical 
application of a popPK model to guide the tacrolimus (starting) 
dose may shorten the time to reach the target tacrolimus C0, 
minimize underexposure and overexposure, and improve clinical 
outcomes.26,28
Few of these popPK models and dosing equations were success-
fully validated externally,6,15,24,29 and/or tested prospectively.18,30 
Only one popPK model (which included CYP3A5 genotype and 
comedication) predicted the required tacrolimus dose successfully 
when applied in clinical practice.18 However, the latter popPK 
model cannot be used in White patients, because it was developed 
and tested in an Asian population.18
In the present prospective, single- arm, therapeutic interven-
tion study, it was investigated whether a tacrolimus starting dose 
based on a previously developed dosing algorithm,11 leads to a 
sufficient percentage of patients being within the tacrolimus tar-
get C0 range on day 3 after transplantation, with respect to the 
percentage found in a historic control group of patients who re-
ceived a standard tacrolimus starting dose based on bodyweight 
alone.7
PATIENTS AND METHODS
This study was an investigator- initiated, prospective, single- arm, 
therapeutic intervention trial, in which kidney transplant recipi-
ents were prescribed a tacrolimus starting dose based on a dosing 
algorithm,11 rather than a standard bodyweight- based starting 
dose.
Patient population
Patients were eligible for participation in this study if they were 
at least 18  years old and were scheduled to undergo a HLA 
and blood group ABO compatible kidney transplantation 
with a living donor in the Erasmus MC, University Medical 
Center Rotterdam, The Netherlands. Patients had to receive 
tacrolimus as part of their initial immunosuppressive therapy. 
Exclusion criteria were (1) tacrolimus treatment in the 28 days 
before the kidney transplantation, (2) the use of drugs having a 
pharmacokinetic interaction with tacrolimus (Table S1) in the 
28 days prior to the kidney transplantation, or (3) a multi- organ 
transplantation.
Intervention and additional immunosuppressive treatment
All patients included in this trial received a tacrolimus start-
ing dose (Prograft; Astellas Pharma, Leiden, The Netherlands) 
based on an internally and externally validated dosing algo-
rithm, as described by Andrews et al.,11 rather than the stan-
dard, bodyweight- based starting dose (0.2  mg/kg/day). The 
algorithm included age, BSA, and CYP3A4 and CYP3A5 geno-
types. Carriers of at least one CYP3A5*1 allele were considered 
CYP3A5 expressers.11
The calculated total daily dose was divided in two equal doses which 
were rounded off to the nearest 0.5 mg and administered to each pa-
tient every 12 hours (at 10:00 and 22:00 hours, starting on the night 
after transplant surgery). Patients received 5 unaltered doses of the 
calculated tacrolimus dose until the morning of postoperative day 3, 
which was considered the first steady- state concentration. Thereafter, 
TDM was performed as part of routine clinical care aiming for whole- 
blood tacrolimus C0 of 7.5 to 12.5 ng/mL in weeks 1 to 2.
All patients received induction therapy with basiliximab 
(Simulect; Novartis Pharma B.V., Arnhem, The Netherlands; 
20  mg on days 0 and 4 after transplantation), mycopheno-
late mofetil (Cellcept; Roche Pharmaceuticals, Woerden, The 
Netherlands; started in a dose of 1,000  mg orally twice daily, 
aiming for a plasma C0 of 1.5– 3.0  mg/L) and glucocorticoids. 
Patients received i.v. prednisolone in a dose of 50  mg twice 
daily on days 0– 3. Thereafter, patients were administered an 
oral dose of 20  mg prednisolone once daily (days 4– 14 post- 
transplantation), after which the dose was lowered to 15  mg 
once daily (days 15– 28) and then tapered to 5 mg at month 3 
post- transplantation.
CYP3A genotyping
During their work- up for living donor kidney transplantation, 
patients were genotyped for CYP3A4 and CYP3A5. DNA 
was extracted from buccal mucosa, which was collected with 
a buccal swap. Samples were analyzed for the presence of the 
CYP3A4*1/*22 and CYP3A5*1/*3 single- nucleotide poly-
morphisms using Autogenomics INFINITY micro- arrays 
(Autogenomics, Carlsbad, CA), according to the manufactur-
er’s instructions. Genotyping was performed in accordance 
with standard laboratory procedures in an ISO15189 certi-
fied laboratory. For the calculation of the starting dose,11 pa-
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Tacrolimus sampling and measurement
Blood samples were collected for tacrolimus C0 measurement 
on postoperative days 3, 5, 7, and 10 during hospitalization and 
whenever deemed necessary by the attending physician (but not 
before day 3). Moreover, the tacrolimus C0 was measured on 
the morning of a for- cause transplant biopsy. A validated liquid 
chromatography- tandem mass spectrometry method was used 
to determine tacrolimus concentrations in whole- blood samples 
in an ISO15189 certified laboratory. The imprecision of this 
method is <  10% with a bias <  15% over the validated range 
1.0– 35.0 ng/mL.
Study end points
The aim of this study was to increase the percentage of pa-
tients with a tacrolimus C0 within the therapeutic range and 
to minimize the occurrence of tacrolimus underexposure and 
overexposure in the early phase after renal transplantation 
by using a dosing algorithm to guide the tacrolimus starting 
dose. The primary end point of this study was the proportion 
of patients within the target tacrolimus C0 range (7.5– 12.5 ng/
mL) on the morning of the third day after renal transplanta-
tion. The outcomes were interpreted with respect to a histori-
cal control group, in which renal allograft recipients received a 
tacrolimus starting dose based on bodyweight (0.2 mg/kg per 
day).7 Moreover, the tacrolimus C0 that patients would have 
had if they would have received a standard bodyweight- based 
tacrolimus dose was estimated (see below) to evaluate model 
performance.
Secondary study end points were (1) the proportion of pa-
tients with a markedly supratherapeutic (>  20  ng/mL) or 
subtherapeutic (< 5 ng/mL) tacrolimus C0 on the third day post- 
transplantation, (2) the proportion of patients within the tacro-
limus target C0 range on postoperative days 5, 7, and 10, and 
(3) the time to reach the target tacrolimus C0. Secondary clin-
ical end points included the incidence of biopsy- proven acute 
rejection (BPAR), post- transplant diabetes mellitus (PTDM), 
and the number of serious adverse events (SAEs) within the first 
30 days post- transplantation. Biopsies were performed for- cause 
only and were assessed and graded according to the Banff 2019 
update by a renal pathologist.31 PTDM was defined as the use of 
glucose- lowering medical therapy on day 30 post- transplantation 
in a patient not needing such treatment before transplantation. 
The following data on renal function was collected: serum cre-
atinine concentration, Chronic Kidney Disease Epidemiology 
Collaboration estimated glomerular filtration rate, and the pro-
tein/creatinine ratio in urine.32 The total follow- up period was 
30 days after renal transplantation.
Sample size calculation and statistical analysis
A Simon 2- stage design was used for sample size calculation.33 
In a historical cohort, consisting of 99 patients transplanted in 
the Erasmus MC, 37.4% of the patients treated with the stan-
dard, bodyweight- based tacrolimus starting dose had a tacro-
limus C0 within the target range (10– 15  ng/mL) on the third 
day post- transplantation.7 With algorithm- based dosing, a pro-
portion of 55% of the patients was expected to be within the 
target tacrolimus C0 range on the third day post- transplantation. 
Therefore, P0 = 37.4% and P1 = 55.0% were used as design pa-
rameters. Together with α  =  0.10 and β  =  0.10, the required 
number of patients in this study was 56, with one preplanned 
interim analysis after the first 27 included patients. If, after the 
inclusion of 56 patients, at least 26 patients had a tacrolimus C0 
within the target range on the third day post- transplantation, 
the conclusion of this trial would be that algorithm- based dos-
ing is effective and results in a sufficiently high proportion of 
patients with an adequate tacrolimus C0 to warrant further re-
search in this population. To account for a dropout rate of 7%, 
a total of 60 patients was included in this clinical trial. If at the 
interim analysis, only ≤  10 of the first 27 patients would have 
had a tacrolimus C0 within the therapeutic target range on day 
3 after transplantation, inclusion of further patients would have 
been terminated, otherwise inclusion would be extended to a 
total of 60 patients.
All statistical analyses were performed in R (version 3.5.3)34 
following an intention- to- treat approach. Only in case of a pro-
tocol violation (i.e., if the tacrolimus concentration was mea-
sured before the third post- operative day resulting in a dose 
adjustment), the patient was excluded from the analysis. The 
primary end point is presented as number of cases with a tacro-
limus C0 within the target range with a proportion and a 90% 
confidence interval (CI). Descriptive statistics were used to eval-
uate secondary end points of the study population. Categorical 
variables were described as number of cases with a percentage. 
Continuous variables were described as median with interquar-
tile range (IQR). A Kaplan– Meier survival analysis was used to 
evaluate the time to target concentration.
Estimated tacrolimus C0
In order to evaluate the performance of the model, we estimated 
the tacrolimus C0 that patients would have had if they would have 
received a standard bodyweight- based tacrolimus starting dose. 
The estimated tacrolimus C0 was calculated using the following 
information: the algorithm- based dose (administered), the ob-
served tacrolimus C0 on day 3 (measured), and the bodyweight- 
based dose (not administered):
Ethical considerations
This clinical trial was performed in accordance with the 
principles of the Declaration of Helsinki (seventh revision, 
October 2013, approved by the 64th WMA General Assembly, 
Fortaleza, Brazil) and the Medical Research Involving Human 
Subjects Act (WMO). Study procedures were performed in ac-
cordance with the ethical standards of the institutional research 
committee (Erasmus MC Medical Ethical Review Board, num-
ber 2018- 157). The trial was registered (19- 10- 2018) in the 
Dutch national trial registry (https://www.trial regis ter.nl/
trial/ 7360). Written informed consent was obtained from all 
patients prior to inclusion.
Estimated tacrolimus C0 =
bodyweight based dose ∗ observed tacrolimus C0
algorithm based dose
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RESULTS
In the period of February 23, 2019 (first patient, first visit) 
until July 7, 2020 (last patient, first visit), 227 patients received 
a kidney transplant at the Erasmus MC. Ninety- seven (42.7%) 
of these patients were eligible for participation in this study, of 
whom 60 patients were included (Figure 1). After inclusion, in 
one patient, the tacrolimus concentration was inadvertently mea-
sured before the third post- operative day (before steady- state), 
followed by a dose adjustment. This patient was considered to 
have a protocol violation and was excluded from the analysis, re-
sulting in a total of 59 patients for the intention- to- treat analysis.
Baseline characteristics
Table 1 presents the baseline characteristics of the included patients. 
The median age at the time of transplantation was 59 years (IQR 48– 
67). White ethnicity was the most prevalent (90%). CYP3A4 and 
CYP3A5 genotype frequencies (Table 1) were in accordance with 
the Hardy– Weinberg equilibrium (χ2 = 0.40; P = 0.53 and χ2 = 1.03; 
P = 0.31, respectively). Nine participants (15%) carried a CYP3A4*22 
allele and 14 participants (24%) were CYP3A5 expressers (carriers 
of at least one *1 allele). None of the patients started comedication 
known to interact with tacrolimus during the study period.
Primary end point: Achievement of the target range
Thirty- four of the 59 patients (58%; 90% CI 47%– 68%) had a tac-
rolimus C0 within the target concentration range (7.5– 12.5 ng/mL) 
on day 3 after transplantation (Table 2; Figure 2). The median tac-
rolimus C0 on day 3 was 8.4 ng/mL (IQR 6.9– 10.4). The median 
algorithm- based starting dose was 10.0 mg/day (IQR 9.0– 14.5).
Secondary pharmacokinetic end points
Seventeen patients (29%; 90% CI 19%– 39%) had a tacrolimus C0 
below 7.5 ng/mL, whereas 8 patients (14%; 90% CI 6%– 21%) had 
a tacrolimus C0 above 12.5 ng/mL (Table 2; Figure 2). Four of 59 
patients (7%; 90% CI 1%– 12%) had a markedly low tacrolimus C0 
(< 5.0 ng/mL) and 2 patients (3%; 90% CI 0%– 7%) had a mark-
edly high tacrolimus C0 (> 20.0 ng/mL; Table 2).
The median time to reach the target tacrolimus C0 for the first 
time, was 3 days (Figure 3). On day 5 post- transplantation, 35 of 
57 patients (61%; 90% CI 51%– 72%) had a tacrolimus C0 concen-
tration within the target range. This increased to 29 of 44 patients 
(66%; 90% CI 54%– 78%) on day 7 and to 25 of 37 patients (68%; 
90% CI 55%– 80%) on day 10 after transplantation (Figure  2). 
The other patients had been discharged from the hospital before 
postoperative day 10 and, therefore, no blood samples of these 
Figure 1 Flowchart of the trial depicting the inclusion and exclusion of patients. ABOi, blood group incompatibility; HLAi, human leukocyte 
antigen incompatibility.
Number of transplantations in the Erasmus MC in the 
period 23 February 2019 - 07 July 2020
n = 227
Transplantation with a deceased donor
n = 108
Number of patients meeting the inclusion criteria
n = 97
Number of transplantations from a living donor
n = 119
Patients not meeting the inclusion criteria (n = 22)
- Tacrolimus use pre-transplant n = 10
- No tacrolimus-based therapy n = 2
- AB0i / HLAi n = 6
- Multi-organ transplantation n = 1
- Use of interacting drugs n = 3
Number of patients included in the study
n = 60
Reasons for non-inclusion (n = 37)
- No consent for participation n = 4
- Participation in other trial n = 20
- Missed n = 8
- Other reasons n = 5
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patients were available. The median number of dose adjustments 
to reach the tacrolimus target range was 0 (range 0– 2). The median 
number of dose- adjustments up until day 10 after transplantation 
was 1 (range 0– 3).
Estimated tacrolimus C0 after bodyweight- based dosing
The median calculated bodyweight- based dose (0.2  mg/kg; not 
administered) was 16.0 mg/day (IQR 14.0– 18.0). The difference 
between the algorithm- based (administered) and the bodyweight- 
based (hypothetical) starting dose of the participants in this 
trial ranged between −14.0 mg and + 6.0 mg, with a median of 
−5.0 mg (Table 2). This indicates that in most patients, the algo-
rithm recommended a lower dose than standard. This was most 
pronounced in obese patients and in CYP3A5 nonexpressers 
(Table S2; Figures S1, S2).
The median estimated tacrolimus concentration on day 3 after 
transplantation was 11.4 ng/mL (IQR 8.5– 17.8; range 4.2– 49.5). 
Of 59 patients, 23 (39%) were estimated to have been within the 
target tacrolimus concentration range if their starting dose would 
have been based on bodyweight alone rather than on the algo-
rithm (Figure S3). Nine patients (15%) were estimated to have 
had a subtherapeutic tacrolimus C0 on day 3, whereas 27 patients 
(46%) would have been expected to have reached a supratherapeu-
tic tacrolimus C0 at this same time point. One patient (2%) was 
estimated to have reached a tacrolimus C0 < 5.0 ng/mL, and 10 pa-
tients (17%) were estimated to have had a tacrolimus C0 > 20 ng/
mL. These data demonstrate that the algorithm mainly reduced 
the incidence of tacrolimus overexposure.
Clinical outcomes
All 59 patients that were included in this analysis, survived the 
first post- transplant month, and completed the 30- day follow- up. 
At the end of follow- up, all patients had a functioning graft. At day 
30, the median serum creatinine concentration was 134 µmol/L 
(IQR 110– 162), the median estimated glomerular filtration rate 
was 46 mL/min per 1.73 m2 (IQR 39– 52), and the median urinary 
Table 1 Baseline characteristics
Recipient characteristics Study population (n = 59)
Gender
Female/Male 22 (37%)/37 (63%)
Age (years) 59 (IQR 48– 67; 
range 19– 83)
Bodyweight (kg) 80.0 (IQR 71.2– 90.0; 
range 49.3– 119.5)
Length (cm) 176.0 (IQR 170.0– 180.5; 
range 156.0– 202.0)
BMI (kg/m2) 26.2 (IQR 23.5– 28.9; 
range 17.7– 37.2)








*22 carrier/*22 non- carrier 9 (15%)/50 (85%)
CYP3A5 genotype
Expresser/non- expresser 14 (24%)/45 (76%)
RRT prior to kidney transplantation
Hemodialysis 14 (24%)
Peritoneal dialysis 9 (15%)
Pre- emptive 36 (61%)
Number of kidney transplantations
1st/2nd/3rd 58 (98%)/0 (0%)/1 (2%)
Donor type
Living related/Living unrelated 20 (34%)/39 (66%)
PRA current
<15%/>15% 55 (93%)/4 (7%)
PRA peak
<15%/>15% 56 (95%)/3 (5%)
Continuous variables are described as median (IQR; range). Categorical 
variables as number of cases (%).
BMI, body mass index; PRA, panel reactive antibodies; RRT, renal replacement 
therapy.
Table 2 Pharmacokinetic outcomes
Outcome (n = 59)
Tacrolimus doses
Algorithm- based dose, mg/day 10.0 (IQR 9.0– 14.5; 
range 6.0– 22.0)
Bodyweight- based dose,  
mg/day
16.0 (IQR 14.0– 18.0; 
range 10.0– 24.0)
Dose difference, mg/day −5.0 (IQR −7.0 to −2.0; 
range −14.0– 6.0)
Primary end point
On target day 3, n 34 (58%; 90% CI 47%– 68%)
Tacrolimus concentration day 
3, ng/mL
8.4 (IQR 6.9– 10.4; 
range 3.9– 33.0)
< 7.5 ng/mL day 3, n 17 (29%; 90% CI 19%– 39%)
> 12.5 ng/mL day 3, n 8 (14%; 90% CI 6%– 21%)
Secondary end points
< 5.0 ng/mL day 3, n 4 (7%; 90% CI 1%– 12%)
> 20.0 ng/mL day 3, n 2 (3%; 90% CI 0%– 7%)
On target day 5, n 35/57 (61%; 90% CI 51%– 72%)
On target day 7, n 29/44 (66%; 90% CI 54%– 78%)
On target day 10, n 25/37 (68%; 90% CI 55%– 80%)
Tac concentration day 5,  
ng/mL
9.0 (IQR 7.8– 11.9; 
range 5.8– 22.2)
Tac concentration day 7,  
ng/mL
10.4 (IQR 9.2– 12.3; 
range 5.3– 25.7)
Tac concentration day 10,  
ng/mL
10.4 (IQR 9.0– 12.7; 
range 5.3– 21.3)
Continuous variables are described as median (IQR; range). Categorical 
variables as number of cases, n (%, 90% confidence interval).
CI, confidence interval; IQR, interquartile range.
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Figure 2 (a) Boxplot of the tacrolimus C0 on days 3, 5, 7, and 10 after transplantation. The box corresponds with the 25th percentile (lower 
boundary), the median (middle line), and the 75th percentile (upper boundary). The upper whisker reaches to the highest value up until 1.5 
times the interquartile range (IQR). The lower whisker reaches the lowest value up until 1.5 times the IQR. Values outside these ranges are 
considered outliers and are represented as dots. The grey area represents the target tacrolimus C0 range (7.5– 12.5 ng/mL). (b) Spaghetti plot 



























































(b) Individual tacrolimus concentrations on days 3, 5, 7, and 10
Figure 3 Kaplan– Meier curve depicting the time to the first achievement of a tacrolimus concentration within the target range (7.5– 12.5 ng/
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The time to the first achievement of the tacrolimus target concentration range
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protein/creatinine ratio was 21.8  g/mol creatinine (IQR 12.1– 
30.3). The median length of hospital stay was 10 days (IQR 7– 10).
BPAR complicated transplantation in 3 patients within 30 days 
after transplantation (5%; Table 3). In one of these three patients, 
acute T- cell- mediated rejection was also diagnosed in a follow- up 
biopsy (and treated with alemtuzumab). In one patient, borderline 
(suspicious) for acute T- cell mediated rejection was diagnosed 
(and treated with methylprednisolone).
Eight other patients received antirejection therapy. Three of 
these patients had histomorphological signs suspicious for active 
antibody- mediated rejection (aABMR) in their biopsy, but did 
not meet the full Banff 2019 criteria for this diagnosis. Of these 
three, one patient had microvascular inflammation suspicious for 
aABMR, but immunohistochemistry was negative for C4d and no 
donor- specific anti- HLA antibodies were detected. Two of these 
three patients had thrombotic microangiopathy, but a negative 
C4d staining and again, no evidence of donor- specific anti- HLA 
antibodies. All three patients were treated with methylprednis-
olone and i.v. immunoglobulins. Three other cases were treated 
for rejection pending the results of the biopsy but only had acute 
tubular necrosis in their biopsy. The two remaining patients had 
presumed clinical rejection and antirejection treatment was started 
but no biopsy was performed (because of the use of anticoagulant 
therapy in one case and improvement of kidney function after an-
tirejection treatment in the other case).
On the day of the biopsy (on days 3, 7, and 8 post- transplantation, 
respectively) the three patients with BPAR had a tacrolimus C0 
of 4.4, 10.4, and 11.7  ng/mL, respectively (Figure S4). On day 
3 after transplantation, 2 of the patients with BPAR were on tar-
get; the third patient with BPAR had a tacrolimus C0 of 4.4 ng/
mL at first steady- state. This patient was a 65- year- old man with a 
bodyweight of 85.5 kg, a BSA of 2.05 m2, and a CYP3A4*1/*1 and 
CYP3A5*3/*3 genotype. Additional post hoc genotyping demon-
strated that he had the POR*1/*28 genotype. He did not use any 
interacting comedication and did not receive erythrocyte transfu-
sions. He was discharged on day 11 with a tacrolimus dose of 5 mg 
twice- daily, which corresponded exactly to the starting dose pre-
dicted by the algorithm.
A total of 21 SAEs (other than BPAR, borderline rejection, sus-
pected aABMR, acute tubular necrosis treated as rejection, and 
presumed rejection) were reported in 59 participants (Table  4). 
PTDM occurred in six patients (10%).
DISCUSSION
In this prospective intervention trial, a tacrolimus dosing algo-
rithm, which included the covariates age, BSA, and CYP3A4 
and CYP3A5 genotypes,11 successfully predicted the tacrolimus 
starting dose of renal transplant recipients. With algorithm- 
guided tacrolimus dosing, 58% of the patients had a tacrolimus 
C0 within the target concentration range at first steady- state 
(day 3 after transplantation). In a historical cohort in which the 
starting dose was based on bodyweight alone, this was 37.4%.7 
In other studies, even lower proportions of patients reaching the 
target concentration after initial bodyweight- based dosing were 
observed: 18.5% and 29.1%.8,9 Following the decision rules of 
the Simon 2- stage design, we can conclude that algorithm- based 
tacrolimus dosing is effective and results in a sufficiently high 
proportion of patients on target to warrant further research in 
this study population.
The use of algorithm- based dosing seemed to especially reduce 
overexposure in the early phase after renal transplantation. A mark-
edly high tacrolimus concentration was observed in only 3% of the 
renal transplant recipients, whereas this was 19% in the historical 
cohort, in which bodyweight- based dosing was applied. This likely 
relates to the relatively high proportion of CYP3A5 nonexpress-
ers in our mainly White population. These slow metabolizers are 
likely to be overdosed when standard, bodyweight- based doses are 
prescribed. The risk of overexposure following bodyweight- based 
Table 3 Banff 19 classification of rejections occurring 









Total BPAR 3a (5%)
aABMR, active, antibody- mediated rejection; aTCMR, acute T cell- mediated 
rejection; BPAR, biopsy- proven acute rejection; bTCMR, borderline (suspicious 
for) T cell- mediated rejection.
Depicted are the number of patients (%).
 aOne patient had two reported rejection episodes (both classified as aTCMR 
2B).
Table 4 SAEs occurring within the 30 days after 
transplantation
SAE type Events (n = 59 patients)
Acute tubular necrosisa 7b




Respiratory tract infection 1
Urinary tract infection 2c
Surgical or procedural complication
Hydronephrosis 1
Seroma 1





SAEs, serious adverse events.
 aAll diagnosed by kidney transplant biopsy.
 bOne of these patients experienced delayed graft function.
 cUrosepsis in the same patient.
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dosing seems to be especially high in obese patients (body mass 
index > 30 kg/m2), who made up 20.3% of the population of this 
study.
A markedly low tacrolimus concentration was observed in 7% 
of the patients on day 3 post- transplantation, whereas this was 
3% in the historical cohort. Although underexposure seems to 
occur more often than overexposure when using the dosing al-
gorithm, the proportion of patients with BPAR in the present 
study was low (5%) as was expected for a low immunological 
risk population, and appears to be similar to the proportion 
of patients with BPAR after bodyweight- based dosing (6.7% 
within the first month and 10.1% within 3 months after renal 
transplantation).7 We could not identify factors that caused the 
low tacrolimus C0 in the one patient that experienced BPAR and 
early underexposure. Although this patient had the POR*1/*28 
genotype (associated with a higher tacrolimus dose require-
ment), an effect of this polymorphism has only been observed 
in CYP3A5 expressers.35– 37 The present incidence of PTDM of 
10% is in line with literature.38,39 Although a number of SAEs 
occurred, this is not unexpected in a renal transplant popula-
tion and the SAEs seemed not to be related to the use of the 
dosing algorithm. Because tacrolimus underexposure and over-
exposure have been associated with an increased risk of rejection 
and drug- related toxicity, respectively,12,40,41 it is important to 
minimize the time a patient’s tacrolimus exposure is outside the 
target range. In this trial, the median time to achieve the tar-
get concentration was 3 days. In the historical cohort, a median 
time to reach the target concentration of 6 days was observed, 
whereas this was 7 days in another study.7,9
The slow increase in the proportion of patients with tacroli-
mus concentrations within the target range after the third post-
operative day can be partly explained by intrapatient variability, 
as some patients with a tacrolimus C0 within the target range 
on a certain day had a tacrolimus C0 outside the target range on 
a subsequent day. This may be explained by changes in, among 
others, the concentration of tacrolimus- binding proteins (in-
cluding albumin) and hematocrit. Computerized dosing after 
transplantation may further improve tacrolimus treatment. In a 
randomized, controlled trial by Størset et al.,42 kidney transplant 
recipients in the experimental arm were treated with computer- 
based tacrolimus dosing. In the control arm, tacrolimus doses 
were adjusted by experienced clinical staff. All patients received 
a bodyweight- based tacrolimus starting dose and then a tacro-
limus C0 was determined on day 1 or 2 post- transplantation. 
Subsequent tacrolimus doses were then based on this C0 by ei-
ther the computer or the clinician. The trial of Størset et al.42 
demonstrated that computerized dosing leads to a higher pro-
portion of patients within the tacrolimus target C0 range com-
pared with physician- based dosing. Together with the results of 
the present trial, we think that, in the future, a further refine-
ment of tacrolimus therapy may be achieved by using comput-
erized dosing for both the calculation of the tacrolimus starting 
dose, and for subsequent dose adjustments.
A limitation of this study is its single- arm design. Therefore, 
it does not provide the ultimate proof that algorithm- based tac-
rolimus start- dosing outperforms standard, bodyweight- based 
dosing. This question can only be answered by a randomized, 
controlled clinical trial. Because several previously developed 
algorithms did not perform well when tested prospectively,18,30 
we decided to first investigate the clinical efficacy of our algo-
rithm in this single arm pilot study before embarking on a large 
randomized, controlled clinical trial. Another limitation of this 
trial is the fact that different target tacrolimus concentration 
ranges were aimed for in the present and historical cohort. This 
reflects the changed clinical practice.43,44 In the historical co-
hort, which was used for the power calculation, the tacrolimus 
target concentration ranged from 10.0 to 15.0 ng/mL, whereas 
the target concentration in the present trial ranged from 7.5 
to 12.5  ng/mL (which is also the current target range for rou-
tine clinical practice in our center). When looking back at the 
data of the historical cohort, 36.4% of the patients with a stan-
dard, bodyweight- based dose, had a tacrolimus concentration 
within the 7.5– 12.5 ng/mL concentration range on day 3 post- 
transplantation. Because this proportion is even lower than the 
37.4% we used to design the present study, we feel that adapta-
tion of the target tacrolimus concentration range of the historical 
cohort for the determination of the decision parameters, would 
not have altered the conclusions of this trial. Third, a signifi-
cant number of patients had a tacrolimus concentration outside 
the target concentration range despite the use of the algorithm. 
The causes of this unexplained variability are unclear, but may 
relate to other genetic variation in tacrolimus- metabolizing en-
zymes35,37,45 or to interindividual differences in the intestinal 
microbiome.46– 48 Finally, the present algorithm was not tested 
in recipients of a deceased donor kidney transplant. We are cur-
rently improving our algorithm so that it can be used for all types 
of kidney transplantation.
In conclusion, basing the tacrolimus starting dose on a dosing 
algorithm is effective in the prediction of an individual’s tacrolimus 
dose requirement as it leads to the achievement of the tacrolimus 
target C0 in as much as 58% of the patients on day 3 after kidney 
transplantation. Although a randomized clinical trial is required to 
demonstrate the superiority of algorithm- based dosing over con-
ventional bodyweight- based dosing, the use of a dosing- algorithm 
appears to reduce off- target exposure to tacrolimus in the critical 
early phase after transplantation and therefore has the potential to 
improve clinical outcomes.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
ACKNOWLEDGMENTS
The authors would like to thank Mrs. Oudhuizen- van Reen and Mrs. van 
Oers for the clinical assistance in the collection of the blood samples.
FUNDING
No funding was received for this work.
CONFLICTS OF INTEREST
D.A.H. has received grant support (paid to his institution) from Astellas 
Pharma, Chiesi Farmaceutici SpA, and Bristol Myers- Squibb, as well as 
lecture and consulting fees from Astellas Pharma, Chiesi Farmaceutici 
SpA, Novartis Pharma, and Vifor Pharma. In the last 3  years, T.v.G. 
has received lecture fees and study grants from Chiesi and Astellas, 
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 0 NUMBER 0 | Month 2021 9
in addition to consulting fees from Roche Diagnostics, Vitaeris, CSL 
Behring, Astellas, Aurinia Pharma, and Novartis. M.C.C.- v.G. received 
grant support from Astellas Pharma (paid to the Erasmus MC). All other 
authors declared no competing interests for this work.
AUTHOR CONTRIBUTIONS
M.I.F., B.C.M.d.W., and D.A.H., wrote the manuscript. L.M.A., T.v.G., 
B.vd.H., B.C.M.d.W., and D.A.H. designed the research. M.I.F., L.M.A., 
H.L.L., J.vd.W., M.C.C.v.G. B.C.M.d.W., R.H.N.v.S and D.A.H. performed 
the research. M.I.F. analyzed the data.
DATA AVAILABILITY
Data were collected in OpenClinica. The data that support the findings of 
this study are available from the corresponding author upon reasonable 
request.
© 2021 The Authors. Clinical Pharmacology & Therapeutics published 
by Wiley Periodicals LLC on behalf of American Society for Clinical 
Pharmacology and Therapeutics.
This is an open access article under the terms of the Creative Commons 
Attribution- NonCommercial- NoDerivs License, which permits use and dis-
tribution in any medium, provided the original work is properly cited, the 
use is non- commercial and no modifications or adaptations are made.
 1. Brunet, M. et al. Therapeutic drug monitoring of tacrolimus- 
personalized therapy: second consensus report. Ther. Drug Monit. 
41, 261– 307 (2019).
 2. Prograf, Summary of product characteristics (European Medicines 
Agency (2006) <https://www.ema.europa.eu/en/docum ents/refer 
ral/progr af-artic le-30-refer ral-annex-i-ii-iii_en.pdf>.
 3. Kidney Disease: Improving Global Outcomes Transplant Working 
Group. KDIGO clinical practice guideline for the care of kidney 
transplant recipients. Am. J. Transplant. 9(suppl 3), S111– S155 
(2009).
 4. Andrews, L.M. et al. Overweight kidney transplant recipients are 
at risk of being overdosed following standard bodyweight- based 
tacrolimus starting dose. Transplant. Direct 3, e129 (2017).
 5. Press, R.R. et al. Explaining variability in tacrolimus 
pharmacokinetics to optimize early exposure in adult kidney 
transplant recipients. Ther. Drug Monit. 31, 187– 197 (2009).
 6. Passey, C., Birnbaum, A.K., Brundage, R.C., Oetting, W.S., Israni, 
A.K. & Jacobson, P.A. Dosing equation for tacrolimus using 
genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72, 
948– 957 (2011).
 7. Shuker, N. et al. A randomized controlled trial comparing the 
efficacy of Cyp3a5 genotype- based with body- weight- based 
tacrolimus dosing after living donor kidney transplantation. Am. J. 
Transplant. 16, 2085– 2096 (2016).
 8. Budde, K. et al. Novel once- daily extended- release tacrolimus 
(LCPT) versus twice- daily tacrolimus in de novo kidney 
transplants: one- year results of phase III, double- blind, 
randomized trial. Am. J. Transplant. 14, 2796– 2806 (2014).
 9. Thervet, E. et al. Optimization of initial tacrolimus dose using 
pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721– 726 
(2010).
 10. Hesselink, D.A. & Hoorn, E.J. Improving long- term outcomes of 
kidney transplantation: the pressure is on. Neth. J. Med. 72, 248– 
250 (2014).
 11. Andrews, L.M. et al. A population pharmacokinetic model to 
predict the individual starting dose of tacrolimus in adult renal 
transplant recipients. Br. J. Clin. Pharmacol. 85, 601– 615 
(2019).
 12. Staatz, C.E. & Tett, S.E. Clinical pharmacokinetics and 
pharmacodynamics of tacrolimus in solid organ transplantation. 
Clin. Pharmacokinet. 43, 623– 653 (2004).
 13. Storset, E., Holford, N., Midtvedt, K., Bremer, S., Bergan, S. 
& Asberg, A. Importance of hematocrit for a tacrolimus target 
concentration strategy. Eur. J. Clin. Pharmacol. 70, 65– 77  
(2014).
 14. Andrews, L.M. et al. Dosing algorithms for initiation of 
immunosuppressive drugs in solid organ transplant recipients. 
Expert Opin. Drug Metab. Toxicol. 11, 921– 936 (2015).
 15. Andreu, F. et al. A new CYP3A5*3 and CYP3A4*22 cluster 
influencing tacrolimus target concentrations: a population 
approach. Clin. Pharmacokinet. 56, 963– 975 (2017).
 16. Han, N. et al. Prediction of the tacrolimus population 
pharmacokinetic parameters according to CYP3A5 genotype 
and clinical factors using NONMEM in adult kidney transplant 
recipients. Eur. J. Clin. Pharmacol. 69, 53– 63 (2013).
 17. Bergmann, T.K., Hennig, S., Barraclough, K.A., Isbel, N.M. & 
Staatz, C.E. Population pharmacokinetics of tacrolimus in adult 
kidney transplant patients: impact of CYP3A5 genotype on 
starting dose. Ther. Drug Monit. 36, 62– 70 (2014).
 18. Chen, S.Y. et al. Individualization of tacrolimus dosage basing on 
cytochrome P450 3A5 polymorphism– a prospective, randomized, 
controlled study. Clin. Transplant. 27, E272– E281 (2013).
 19. Golubovic, B., Vucicevic, K., Radivojevic, D., Kovacevic, S.V., 
Prostran, M. & Miljkovic, B. Total plasma protein effect on 
tacrolimus elimination in kidney transplant patients– population 
pharmacokinetic approach. Eur. J. Pharm. Sci. 52, 34– 40 (2014).
 20. Zuo, X.C. et al. Effects of CYP3A4 and CYP3A5 polymorphisms 
on tacrolimus pharmacokinetics in Chinese adult renal 
transplant recipients: a population pharmacokinetic analysis. 
Pharmacogenet. Genomics 23, 251– 261 (2013).
 21. Asberg, A. et al. Inclusion of CYP3A5 genotyping in a 
nonparametric population model improves dosing of tacrolimus 
early after transplantation. Transpl. Int. 26, 1198– 1207 (2013).
 22. Antignac, M., Barrou, B., Farinotti, R., Lechat, P. & Urien, S. 
Population pharmacokinetics and bioavailability of tacrolimus in 
kidney transplant patients. Br. J. Clin. Pharmacol. 64, 750– 757 
(2007).
 23. Zhao, W. et al. Population pharmacokinetics and 
pharmacogenetics of tacrolimus in de novo pediatric kidney 
transplant recipients. Clin. Pharmacol. Ther. 86, 609– 618 (2009).
 24. Andrews, L.M. et al. A population pharmacokinetic model to 
predict the individual starting dose of tacrolimus following 
pediatric renal transplantation. Clin. Pharmacokinet. 57, 475– 489 
(2018).
 25. Zhang, H.J., Li, D.Y., Zhu, H.J., Fang, Y. & Liu, T.S. Tacrolimus 
population pharmacokinetics according to CYP3A5 genotype and 
clinical factors in Chinese adult kidney transplant recipients. J. 
Clin. Pharm. Ther. 42, 425– 432 (2017).
 26. Woillard, J.B. et al. Tacrolimus updated guidelines through 
popPK modeling: how to benefit more from CYP3A pre- emptive 
genotyping prior to kidney transplantation. Front. Pharmacol. 8, 
358 (2017).
 27. Kirubakaran, R., Stocker, S.L., Hennig, S., Day, R.O. & Carland, 
J.E. Population pharmacokinetic models of tacrolimus in adult 
transplant recipients: a systematic review. Clin. Pharmacokinet. 
59(11), 1357– 1392 (2020).
 28. van Gelder, T. & Hesselink, D.A. Dosing tacrolimus based 
on CYP3A5 genotype: will it improve clinical outcome? Clin. 
Pharmacol. Ther. 87, 640– 641 (2010).
 29. Boughton, O., Borgulya, G., Cecconi, M., Fredericks, S., Moreton- 
Clack, M. & MacPhee, I.A. A published pharmacogenetic 
algorithm was poorly predictive of tacrolimus clearance in an 
independent cohort of renal transplant recipients. Br. J. Clin. 
Pharmacol. 76, 425– 431 (2013).
 30. Andrews, L.M. et al. A population pharmacokinetic model does 
not predict the optimal starting dose of tacrolimus in pediatric 
renal transplant recipients in a prospective study: lessons 
learned and model improvement. Clin. Pharmacokinet. 59(5), 
591– 603 (2020).
 31. Loupy, A. et al. The Banff 2019 Kidney Meeting Report (I): 
updates on and clarification of criteria for T cell- and antibody- 
mediated rejection. Am J Transplant 20(9), 2318– 2331  
(2020).
 32. Levey, A.S. et al. A new equation to estimate glomerular filtration 
rate. Ann. Intern. Med. 150, 604– 612 (2009).
 33. Simon, R. Optimal two- stage designs for phase II clinical trials. 
Control. Clin. Trials 10, 1– 10 (1989).
ARTICLE
VOLUME 0 NUMBER 0 | Month 2021 | www.cpt-journal.com10
 34. R- CoreTeam. R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, 
Austria. <https://www.R-proje ct.org/>.
 35. Elens, L. et al. Impact of POR*28 on the pharmacokinetics of 
tacrolimus and cyclosporine A in renal transplant patients. Ther. 
Drug Monit. 36, 71– 79 (2014).
 36. Zhang, J.J., Zhang, H., Ding, X.L., Ma, S. & Miao, L.Y. Effect of the 
P450 oxidoreductase 28 polymorphism on the pharmacokinetics 
of tacrolimus in Chinese healthy male volunteers. Eur. J. Clin. 
Pharmacol. 69, 807– 812 (2013).
 37. de Jonge, H., Metalidis, C., Naesens, M., Lambrechts, D. 
& Kuypers, D.R. The P450 oxidoreductase *28 SNP is 
associated with low initial tacrolimus exposure and increased 
dose requirements in CYP3A5- expressing renal recipients. 
Pharmacogenomics 12, 1281– 1291 (2011).
 38. Heisel, O., Heisel, R., Balshaw, R. & Keown, P. New onset 
diabetes mellitus in patients receiving calcineurin inhibitors: a 
systematic review and meta- analysis. Am. J. Transplant. 4, 583– 
595 (2004).
 39. Webster, A.C., Woodroffe, R.C., Taylor, R.S., Chapman, J.R. & Craig, 
J.C. Tacrolimus versus ciclosporin as primary immunosuppression 
for kidney transplant recipients: meta- analysis and meta- 
regression of randomised trial data. BMJ 331, 810 (2005).
 40. Gaynor, J.J. et al. Lower tacrolimus trough levels are associated with 
subsequently higher acute rejection risk during the first 12 months 
after kidney transplantation. Transpl. Int. 29, 216– 226 (2016).
 41. US Food and Drug Administration (FDA). (2012). Prograf product 
information, Reference ID 3083402.
 42. Storset, E. et al. Improved tacrolimus target concentration 
achievement using computerized dosing in renal transplant 
recipients– a prospective, randomized study. Transplantation 99, 
2158– 2166 (2015).
 43. Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in 
renal transplantation. N. Engl. J. Med. 357, 2562– 2575 (2007).
 44. Kuypers, D.R., Evenepoel, P., Maes, B., Coosemans, W., 
Pirenne, J. & Vanrenterghem, Y. The use of an anti- CD25 
monoclonal antibody and mycophenolate mofetil enables the 
use of a low- dose tacrolimus and early withdrawal of steroids 
in renal transplant recipients. Clin. Transplant. 17, 234– 241 
(2003).
 45. Hesselink, D.A., Bouamar, R., Elens, L., van Schaik, R.H. & van 
Gelder, T. The role of pharmacogenetics in the disposition of 
and response to tacrolimus in solid organ transplantation. Clin. 
Pharmacokinet. 53, 123– 139 (2014).
 46. Guo, Y. et al. Commensal gut bacteria convert the 
immunosuppressant tacrolimus to less potent metabolites. Drug 
Metab. Dispos. 47, 194– 202 (2019).
 47. Lee, J.R. et al. Gut microbiota and tacrolimus dosing in kidney 
transplantation. PLoS One 10, e0122399 (2015).
 48. Zimmermann, M., Zimmermann- Kogadeeva, M., Wegmann, R. & 
Goodman, A.L. Mapping human microbiome drug metabolism by 
gut bacteria and their genes. Nature 570, 462– 467 (2019).
ARTICLE
